Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway

This publication has 26 references indexed in Scilit:

• Vitamin D2 Analog 19-nor-1,25-Dihydroxyvitamin D2: Antitumor Activity Against Leukemia, Myeloma, and Colon Cancer Cells
  JNCI Journal of the National Cancer Institute, 2003
• New insights into the mechanisms of vitamin D action
  Journal of Cellular Biochemistry, 2003
• Vitamin D Analogs and Breast Cancer
  Published by Springer Nature ,2003
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
  Nature Reviews Cancer, 2002
• Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways
  The American Journal of Pathology, 2002
• Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells
  Blood, 2001
• Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC
  Current Biology, 1998
• Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery
  Cell, 1997
• The Role of the Vitamin D Endocrine System in Health and Disease
  New England Journal of Medicine, 1989
• 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells.
  The Journal of cell biology, 1984